Tag: Immunotherapy
Some Immunosuppressed Do Not Have Anti-Spike Antibodies After COVID-19 Vaccination
IgG anti-spike antibodies undetectable in ~20 percent with immunosuppression who had received three or more COVID-19 vaccines
Most Immunosuppressive Drugs Not Linked to Risk for Cancer
No associations seen for TNF inhibitor, antimetabolite, calcineurin inhibitor, or alkylating agent classes with cancer
Nivolumab + Ipilimumab Tops Ipilimumab Alone in Metastatic Melanoma
Significant improvement seen in progression-free survival for combination of nivolumab and ipilimumab
Immune Checkpoint Inhibitors Can Be Active in Penile Cancer
Worse OS seen in association with visceral metastases, ECOG performance status ≥1, higher neutrophil/lymphocyte ratio
T-Cell Tolerant Fraction Can Predict Immunotherapy Toxicity
Cancer patients with clinically significant immune-related adverse events had significantly lower tolerant fraction
Risks for MDS/Leukemia Increased for Survivors of Common Lymphoid Neoplasms
Risks for therapy-related myelodysplastic syndrome/acute myeloid leukemia elevated, but risks lower in recent years
Atezolizumab Monotherapy Beneficial for NSCLC Ineligible for Platinum-Based Chemo
First-line atezolizumab monotherapy is associated with improved overall survival compared with single-agent chemotherapy
Fecal Microbiota Transplant Effective for Immune-Mediated Colitis
92 percent of 12 patients with refractory immune checkpoint inhibitor-induced colitis achieved clinical remission at end of study
ASCO: Lack of Benefit Seen for Indefinite-Duration Immunotherapy in NSCLC
Lack of significant overall survival advantage seen for indefinite-duration versus fixed-duration immunotherapy
ASCO: Adding Pembrolizumab to Chemo Improves Survival in Cervical Cancer
Overall and progression-free survival increased for persistent, recurrent, or metastatic cervical cancer
